Clinical pharmacology of nervous system diseases.
The well-developed defense barriers of the CNS and the expense of drug therapy limit the pharmacologic options for the treatment of neurologic diseases in horses. New approaches to controlling inflammation in the CNS are improving the outcomes of bacterial meningitis. The appropriate treatment of EPM remains controversial. More research is needed to evaluate the pharmacokinetics and pharmacodynamics of drugs in the CNS of the horse. Behavioral pharmacology has become fashionable in human and small animal medicine, but it needs to be evaluated for the potential of unethical use in performance horses.
Dowling
P M
PM
Department of Veterinary Physiological Sciences, Western College of Veterinary Medicine, Saskatoon, Saskatchewan, Canada.
D000818:Animals; D000831:Animals, Newborn; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D002491:Central Nervous System Agents / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000662:veterinary*; D004679:Encephalomyelitis / Q000188:drug therapy / Q000662:veterinary; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D016920:Meningitis, Bacterial / Q000188:drug therapy / Q000662:veterinary; D001523:Mental Disorders / Q000188:drug therapy / Q000662:veterinary; D011529:Protozoan Infections, Animal / Q000188:drug therapy; D012640:Seizures / Q000188:drug therapy / Q000662:veterinary; D012702:Serotonin Antagonists / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D002491:Central Nervous System Agents; D012702:Serotonin Antagonists